DELRAY BEACH, Fla., Jan. 7, 2014 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has engaged American Capital Ventures, a boutique provider of comprehensive investor relations, financial marketing and capital advisory services to the micro- and small-cap community.
"I am pleased to announce our engagement with American Capital Ventures, a provider of investor relations services to emerging growth companies like ours," commented William J. Caragol, Chairman and CEO of PositiveID. "Over the course of the last year and a half, we have been working diligently to reposition the business to better capitalize on sales and partnership opportunities for both our M-BAND airborne bio-threat detector and Firefly handheld, PCR-based diagnostics device. We are eager to showcase the immense market potential for our molecular diagnostics solutions to investment and analyst communities. American Capital Ventures has been brought on board to assist in this initiative and we believe they will be instrumental in communicating our opportunity to the proper audience and generating greater awareness among investors."
Howard Gostfrand, President of American Capital Ventures, commented, "At the crux of PositiveID is the unwavering determination to help protect U.S. citizens from biological threats. Their M-BAND system is positioned to help our homeland defense teams do just that, while Firefly extends the ability to perform biological testing at the point of need – quickly. We are excited to be working with Bill and his top-notch team on better informing the public and the investment community of the potential of their revolutionary technology and securing the long-term investors needed to get PositiveID to the next level."
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID's future expectations, including the likelihood that there is immense market potential for PositiveID's molecular diagnostics solutions and that American Capital Ventures will be undoubtedly instrumental in communicating PositiveID's opportunity to the proper audience and generating greater awareness among investors, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 16, 2013, and 10-Qs filed on May 20, 2013, August 14, 2013, as amended August 19, 2013, and November 19, 2013, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
CONTACT: PositiveID Corporation Allison Tomek 561-805-8000 email@example.com